Andrew Laslett

PROFESSOR

  • andrew.laslett@monash.edu
  • +61 (3) 9518 5911

Biography

Andrew is an Adjunct Professor with the Australian Regenerative Medicine Institute at Monash University and is Head of Research and Development at Magic Valley. Magic Valley is an early-stage biotechnology company developing meat products from animal stem cells without harming animals. Andrew is internationally recognised for his research and commercialisation activities using pluripotent stem cells. Prior to joining Magic Valley, Andrew was a Research Team and Project Leader with the CSIRO, where he led a pluripotent stem cell biology research team. Other previous appointments include Senior Scientist and Group Leader at the Australian Stem Cell Centre (ASCC), Board member and Director of the Australian Society for Medical Research and Senior Research Fellow at the Monash Institute of Medical Research, Monash University. He obtained his BSc (Hons) and PhD from Monash University prior to undertaking postdoctoral positions in Hong Kong, China and Philadelphia, USA.

Click here for full list of publications on ORCID

Research interests

Pluripotent stem cells, reprogramming, differentiation, cellular agriculture and bioreactors.

Featured Publications

Authors Title Published In

Harvey AJ, O’Brien C, Lambshead J, Sheedy JR, Rathjen J, Laslett AL, Gardner DK.

Physiological oxygen culture reveals retention of metabolic memory in human induced pluripotent stem cells.

PLoS One. 2018 Mar 15;13(3):e0193949. doi: 10.1371/journal.pone.0193949. eCollection 2018.

Lambshead JW, Meagher L, Goodwin J, Labonne T, Ng E, Elefanty A, Stanley E, O’Brien CM, Laslett AL.

Long-term maintenance of human pluripotent stem cells on cRGDfK-presenting synthetic surfaces.

Sci Rep. 2018;8(1):701. doi:10.1038/s41598-018-19209-0. Epub 2018 Jan 15.

Trusler O, Huang Z, Goodwin J, Laslett AL.

Cell surface markers for the identification and study of human naive pluripotent stem cells.

Stem Cell Res. 2017 Dec 2;26:36-43. doi: 10.1016/j.scr.2017.11.017. [Epub ahead of print]

Liu X, Nefzger CM, Rossello FJ, Chen J, Knaupp AS, Firas J, Ford E, Pflueger J, Paynter JM, Chy HS, O’Brien CM, Huang C, Mishra K, Hodgson-Garms M, Jansz N, Williams SM, Blewitt ME, Nilsson SK, Schittenhelm RB, Laslett AL, Lister R, Polo JM.

Comprehensive characterization of distinct states of human naive pluripotency generated by reprogramming.

Nat Methods. 2017 Nov;14(11):1055-1062. doi: 10.1038/nmeth.4436. Epub 2017 Sep 25.

Murphy AR, Ghobrial I, Jamshidi P, Laslett AL, O’Brien CM, Cameron NR.

Tailored emulsion-templated porous polymer scaffolds for iPSC-derived human neural precursor cell culture.

Polym Chem. 2017 Oct;8:351-7. doi: 10.1039/C7PY01375B.

Murphy AR, Laslett AL, O’Brien CM and Cameron, NR.

Scaffolds for 3D in vitro culture of neural lineage cells.

Acta Biomater. 2017 May;54:1-20. doi: 10.1016/j.actbio.2017.02.046. Epub 2017 Mar 1.

O’Brien CM, Chy HS, Zhou Q, Blumenfeld S, Lambshead JW, Liu X, Kie J, Capaldo BD, Chung TL, Adams TE, Phan T, Bentley JD, McKinstry WJ, Oliva K, McMurrick PJ, Wang YC, Rossello FJ, Lindeman GJ, Chen D, Jarde T, Clark AT, Abud HE, Visvader JE, Nefzger CM, Polo JM, Loring JF, Laslett AL.

New monoclonal antibodies to defined cell surface proteins on human pluripotent stem cells. 

Stem Cells. 2017 Mar;35(3):626-640. doi: 10.1002/stem.2558. Epub 2017 Jan 19.

Wang YC, Stein JW, Lynch CL, Tran HT, Lee CY, Coleman R, Hatch A, Antontsev VG, Chy HS, O’Brien CM, Murthy SK, Laslett AL, Peterson SE, Loring JF.

Glycosyltransferase ST6GAL1 contributes to the regulation of pluripotency in human pluripotent stem cells.

Sci Rep. 2015 Aug 25;5:13317. doi: 10.1038/srep13317.

Mason EA, Mar JC, Laslett AL, Pera MF, Quackenbush J, Wolvetang E, Wells CA.

Gene expression variability as a unifying element of the pluripotency network.

Stem Cell Reports. 2014 Aug 12;3(2):365-77. doi: 10.1016/j.stemcr.2014.06.008. Epub 2014 Jul 25.

Xu Y, Liu L, Laslett AL, Esteban MA.

Cell Reprogramming: Into the groove.

Nat Mater. 2013 Dec;12(12):1082-4. doi: 10.1038/nmat3821.

Tian W, Wang Y, Xu Y, Guo X, Wang B, Sun L, Liu L, Cui F, Zhuang Q, Bao X, et al.

The hypoxia-inducible factor renders cancer cells more sensitive to vitamin C-induced toxicity.

J Biol Chem. 2014 Feb 7;289(6):3339-51. doi: 10.1074/jbc.M113.538157. Epub 2013 Dec 26.

Polanco JC, Wang B, Zhou Q, Chy H, O’Brien C, Laslett AL.

Enrichment and purging of human embryonic stem cells by detection of cell surface antigens using the monoclonal antibodies TG30 and GCTM-2.

J Vis Exp. 2013 Dec 6;(82):50856. doi: 10.3791/50856.

Polanco JC, Laslett AL.

Safety assessment of reprogrammed cells prior to clinical applications: Potential approaches to eliminate teratoma formation.

Puripotent Stem Cells. 2013;25:555-566. doi:10.5772/54400

Polanco JC, Ho MSH, Wang B, Zhou Q, Wolvetang E, Mason E, Wells CA, Kolle G, Grimmond SM, Bertoncello I, et al.

Identification of unsafe human induced pluripotent stem cell lines using a robust surrogate assay for pluripotency.

Stem Cells. 2013 Aug;31(8):1498-510. doi: 10.1002/stem.1425.

Lambshead JW, Meagher L, O’Brien C, Laslett AL.

Defining synthetic surfaces for human pluripotent stem cell culture.

Cell Regen. 2013;2(1):7. doi: 10.1186/2045-9769-2-7. Epub 2013 Nov 22.

Nazor KL, Altun G, Lynch C, Tran H, Harness JV, Slavin I, Garitaonandia I, Mueller F-J, Wang Y-C, Boscolo FS, et al.

Recurrent variations in DNA methylation in human pluripotent stem cells and their differentiated derivatives.

Cell Stem Cell. 2012 May 4;10(5):620-34. doi: 10.1016/j.stem.2012.02.013.

Laurent LC, Ulitsky I, Slavin I, Tran H, Schork A, Morey R, Lynch C, Harness JV, Lee SH, Barrero MJ, et al.

Dynamic changes in the copy number of pluripotency and cell proliferation genes in human ESCs and iPSCs during reprogramming and time in culture.

Cell Stem Cell. 2011 Jan 7;8(1):106-18. doi: 10.1016/j.stem.2010.12.003.

Kolle G, Shepherd JL, Gardiner B, Kassahn KS, Cloonan N, Wood DLA, Nourbakhsh E, Taylor DF, Wani S, Chy HS, et al.

Deep-transcriptome and ribonome sequencing redefines the molecular networks of pluripotency and the extracellular space in human embryonic stem cells.

Genome Res. 2011 Dec; 21(12): 2014–2025. doi: 10.1101/gr.119321.110

Amps K, Andrews PW, Anyfantis G, Armstrong L, Avery S, Baharvand H, Baker J, Baker D, Munoz MB, Beil S, et al.

Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage.

Nat Biotechnol. 2011 Nov 27;29(12):1132-44. doi: 10.1038/nbt.2051.

Laurent LC, Nievergelt CM, Lynch C, Fakunle E, Harness JV, Schmidt U, Galat V, Laslett AL, Otonkoski T, Keirstead HS, et al.

Restricted ethnic diversity in human embryonic stem cell lines.

Nat Methods. 2010 Jan;7(1):6-7. doi: 10.1038/nmeth0110-06.

Herszfeld D, Wolvetang E, Langton-Bunker E, Chung TL, Filipczyk AA, Houssami S, Jamshidi P, Koh K, Laslett AL, Michalska A, et al.

CD30 is a survival factor and a biomarker for transformed human pluripotent stem cells.

Nat Biotechnol. 2006 Mar;24(3):351-7. Epub 2006 Feb 26.

Daniszewski M, Nguyen Q, Chy HS, Singh V, Crombie DE, Kulkarni T, Liang HH, Sivakumaran P, Lidgerwood GE, Hernández D, Conquest A, Rooney LA, Chevalier S, Andersen SB, Senabouth A, Vickers JC, Mackey DA, Craig JE, Laslett AL, Hewitt AW, Powell JE, Pébay A.

Single-Cell Profiling Identifies Key Pathways Expressed by iPSCs Cultured in Different Commercial Media.

iScience. 2018 Sep 28;7:30-39. doi: 10.1016/j.isci.2018.08.016.

Ratcliffe JL, Walker M, Eissa AM, Du S, Przyborski SA, Laslett AL et al.

Optimized peptide functionalization of thiol-acrylate emulsion-templated porous polymers leads to expansion of human pluripotent stem cells in 3D culture.

Journal of Polymer Science, Part A: Polymer Chemistry. 2019 Sep 15;57(18):1974-1981. doi: https://doi.org/10.1002/pola.29353

Murphy AR, Haynes JM, Laslett AL, Cameron NR, O’Brien CM.

Three-dimensional differentiation of human pluripotent stem cell-derived neural precursor cells using tailored porous polymer scaffolds. 

Acta Biomater. 2020 Jan 1;101:102-116. doi: 10.1016/j.actbio.2019.10.017.

Goodwin J, Laslett, AL, Rugg-Gunn, PJ.

The application of cell surface markers to demarcate distinct human pluripotent states. 

Exp Cell Res. 2020 Feb 1;387(1):111749. doi: 10.1016/j.yexcr.2019.111749.

Zhao X, Zhu Y, Laslett AL, Chan HF.

Hepatic differentiation of stem cells in 2D and 3D biomaterial systems.

Bioengineering. 2020 Jun;7(2):47. doi:https://doi.org/10.3390/bioengineering7020047

Trusler O, Goodwin J, Laslett AL.

BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery. 

Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188459. doi: 10.1016/j.bbcan.2020.188459.

Liu X, Ouyang JF, Rossello FJ, Tan JP, Davidson KC, Valdes DS, Schröder J, Sun YBY, Chen J, Knaupp AS, Sun G, Chy HS, Huang Z, Pflueger J, Firas J, Tano V, Buckberry S, Paynter JM, Larcombe MR, Poppe D, Choo XY, O’Brien CM, Pastor WA, Chen D, Leichter AL, Naeem H, Tripathi P, Das PP, Grubman A, Powell DR, Laslett AL, David L, Nilsson SK, Clark AT, Lister R, Nefzger CM, Martelotto LG, Rackham OJL, Polo JM.

Reprogramming roadmap reveals route to human induced trophoblast stem cells. 

Nature. 2020 Oct;586(7827):101-107. doi: 10.1038/s41586-020-2734-6.

Rajab N, Angel PW, Deng Y, Gu J, Jameson V, Kurowska-Stolarska M, Milling S, Pacheco CM, Rutar M, Laslett AL, Lê Cao KA, Choi J, Wells CA.

An integrated analysis of human myeloid cells identifies gaps in in vitro models of in vivo biology. 

Stem Cell Reports. 2021 Jun 8;16(6):1629-1643. doi: 10.1016/j.stemcr.2021.04.010.

Man J, Graham T, Squires-Donelly G, Laslett AL.

The effects of microgravity on bone structure and function. 

NPJ Microgravity. 2022 Apr 5;8(1):9. doi: 10.1038/s41526-022-00194-8.

Rajab N, Gearing LJ, Prawer YD, Angel PW, Grimmond SM, Laslett AL, Choi J, Wells CA.

Proliferation is a driver of quorum sensing in an in vitro model of tissue resident macrophages.

bioRxiv. 2022 Jan 1. doi: https://doi.org/10.1101/2022.05.12.491598